SHANGHAI, April 6, 2021 /PRNewswire/ — Shanghai Genechem Co., Ltd. (Genechem), a discovery firm devoted to novel drug goal discovery and improvement of novel therapeutics, in the present day introduced the execution of a worldwide collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed world biopharmaceutical firm, to develop and commercialize a number of bi-specific antibodies (BsAb) primarily based on monoclonal antibody developed by Genechem and antibodies chosen by I-MAB.
“This collaboration is the primary of many that may leverage Genechem’s Good Analysis Observe (GRP) and CHAMP antibody discovery platform, sturdy bioinformatic database, in addition to sturdy improvement experience of synergistic companions, to ship globally aggressive property primarily based on progressive targets. We’re excited to collaborate with I-Mab, a worldwide chief in Oncology and antibody improvement, to carry extra merchandise to handle scientific unmet wants for sufferers in China and globally”, commented Yueqiong Cao, Founder and CEO of Genechem.
About Shanghai Genchem Co., Ltd. (Genechem)
Genechem is a number one innovation analysis firm targeted on the right track discovery/validation, improvement of antibody and cell remedy merchandise towards novel targets, and partnership globally to maximise its portfolio. Based in 2002, now with over 500 staff, Genechem works intently with Analysis Oncologists to translate scientific analysis into therapeutics addressing excessive scientific unmet wants, leveraging its sturdy community of Analysis Oncologists in over 300 hospitals and Good Analysis Observe (GRP platform) which incorporates complete RNAi library, instruments together with genetic typing, bioinformatic evaluation, genetic manipulation, in addition to SOP and challenge administration methods. For extra data, go to http://www.gcbio.com/.
Dr. Tong Zhang
Chief Enterprise Officer
Shanghai Genechem Co., Ltd
SOURCE Shanghai Genchem Co., Ltd. (Genechem)